Canine visceral leishmaniasis (CVL) is a vector-borne zoonotic disease caused by Eight dogs with suspected CVL were analyzed using serological assays (Speed Leish K® (VIRBAC Diagnostics, France) or An Show more
Canine visceral leishmaniasis (CVL) is a vector-borne zoonotic disease caused by Eight dogs with suspected CVL were analyzed using serological assays (Speed Leish K® (VIRBAC Diagnostics, France) or Antigen Rapid CaniV-4 (Leish)® (BIONOTE, Mexico)), five dogs were detected in 2023, and three during 2025. Histopathological staining was applied in cases with spleen, dermal, and lymph node involvement to determine the presence of Four dogs showed various clinical manifestations that included persistent anemia, thrombocytopenia, splenomegaly, exfoliative dermatitis, and onychogryphosis, whereas the other four dogs remained subclinical or asymptomatic. Histopathological analysis revealed numerous intracellular amastigotes in lymph node aspirates, spleen sections, and ear skin biopsy. Moreover, seven out of eight dogs were positive in the serological analysis, and the other seven to the Infection with Show less
Clonal hematopoiesis (CH) is a common premalignant state in the blood and confers an increased risk of blood cancers and all-cause mortality. Identification of therapeutic targets in CH has been hinde Show more
Clonal hematopoiesis (CH) is a common premalignant state in the blood and confers an increased risk of blood cancers and all-cause mortality. Identification of therapeutic targets in CH has been hindered by the lack of an ex vivo platform amenable for studying primary hematopoietic stem and progenitor cells (HSPCs). Here, we utilize an ex vivo co-culture system of HSPCs with bone marrow endothelial cells to perform CRISPR/Cas9 screens in mutant HSPCs. Our data reveal that loss of the histone demethylase family members Kdm3b and Jmjd1c specifically reduces the fitness of Idh2- and Tet2-mutant HSPCs. Kdm3b loss in mutant cells leads to decreased expression of critical cytokine receptors including Mpl, rendering mutant HSPCs preferentially susceptible to inhibition of downstream JAK2 signaling. Our study nominates an epigenetic regulator and an epigenetically regulated receptor signaling pathway as genotype-specific therapeutic targets and provides a scalable platform to identify genetic dependencies in mutant HSPCs. Significance: Given the broad prevalence, comorbidities, and risk of malignant transformation associated with CH, there is an unmet need to identify therapeutic targets. We develop an ex vivo platform to perform CRISPR/Cas9 screens in primary HSPCs. We identify KDM3B and downstream signaling components as genotype-specific dependencies in CH and myeloid malignancies. See related commentary by Khabusheva and Goodell, p. 1768. Show less